(MENAFN- GlobeNewsWire - Nasdaq) KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed ReleaseTM (PTRTM) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it will participate in the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Los Angeles, California, on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private one-on-one meetings.
Cingulate Chairman & CEO Shane J. Schaffer is scheduled to present a company overview on June 6th at 9:30 a.m. PST. A webcast of the presentation will be available on the investors section of Cingulate's corporate site at .
Cingulate's lead Phase 3 candidate, CTx-1301, is a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD). In addition to the Company's initial focus on the $22bn ADHD market, Cingulate is identifying other indications, such as anxiety, where it's PTRTM technology may be effectively utilized.
To arrange a meeting with Cingulate, please contact your LD Micro representative, or Cingulate investor relations at .
About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary PTRTM drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of neurological disorders, Cingulate is identifying and evaluating additional therapeutic areas where PTRTM technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information visit cingulate.com .
Investor Contact :
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
913-942-2301
Matt Kreps
Darrow Associates Investor Relations
214-597-8200
Tags adhd anxiety benzinga bloomberg cing cingulate ctx-1301 kansas city ld micro phase 3 precision timed release ptrtm
MENAFN25052023004107003653ID1106319077
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.